<unk> (sCD40L) is contained in platelet granules and thus its presence in the blood is a marker of platelet activation. By interacting with<unk> , which is found on endothelial and smooth muscle cells, sCD40L may trigger the release of inflammatory mediators, lead to increased activity of matrix metalloproteinases, and activate the coagulation cascade.
Several recent studies have demonstrated that sCD40L is a powerful and independent predictor of outcome in ACS  . GP IIb/IIIa inhibitors can blunt the magnitude of sCD40L release.<unk> <unk> L elevation identifies a subset of patients who appear to enjoy the greatest benefit from GP IIb/IIIa inhibition, regardless of troponin status.
Soluble CD40 ligand 
Cell adhesion molecule
Tumor necrosis factor receptor
Interleukin-8 receptor
Pattern recognition receptor
Immunoglobulin heavy chain
Receptor tyrosine kinase
Tumor M2-PK